An investigation on behalf of investors in Zai Lab Limited (NASDAQ:ZLAB) shares over potential wrongdoing at Zai Lab Limited was announced.

San Diego, CA -- (SBWire) -- 11/15/2023 --An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Zai Lab Limited.

Investors who purchased shares of Zai Lab Limited (NASDAQ: ZLAB) a have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Zai Lab Limited directors breached their fiduciary duties and caused damage to the company and its shareholders.

China based Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Zai Lab Limited reported that its annual Total Revenue rose from $48.95 million in 2020 to $144.31 million in 2021, and that its Net Loss increased from $268.9 million in 2020 to $704.47 million in 2021.

On March 9, 2022, the U.S. Securities and Exchange Commission ("SEC") published a notification identifying Zai Lab Limited, among other companies, as in potential violation of the Holding Foreign Companies Accountable Act, which allows the SEC to delist companies and ban a company's shares from being traded if the company fails to allow U.S. regulators to review their company audits for three straight years. Zai Lab Limited and the other companies named in the SEC notification have until March 29, 2022 to challenge the charges against them.

Shares of Zai Lab Limited (NASDAQ: ZLAB) declined from $181.92 per share in June 2021, to as low as $25.74 per share on March 14, 2022.

On June 6, 2023, Zai Lab reported phase 3 trials for an oncology therapy it is developing with NovoCure. It said that its tumor treating fields (TTFields) therapy, which uses skin patches to deliver electric fields to areas of the body, when used with standard therapies, met its primary endpoint of three-month improvement in median overall survival time in metastatic non-small cell lung cancer (NSCLC) patients. However the study was unreliable because many of the study participants didn't use an initial checkpoint inhibitor, which is seen as the leading way to treat NSCLC, thereby allowing for the possibility that the study was highly skewed by comparing TTFields to a lesser therapy.

Shares of Zai Lab Limited (NASDAQ: ZLAB) declined from $37.92 per share on June 2, 2023, to as low as $27.08 per share on June 14, 2023.

Those who purchased shares of Zai Lab Limited (NASDAQ: ZLAB) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About The Shareholders Foundation
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.